CCRM
Jaye (Guangqi) Zhou, PhD, currently serves as MSAT Associate Scientist II at CCRM since April 2022, leading technology transfer for various internal and GMP Fee-for-Service projects, including iPSC banking and gene-editing. Prior to this, Jaye held positions as MSAT Associate Scientist I at Index Biosystems, focusing on yeast engineering and microbiology experiments, and as a Research Scientist in Microbiology at Spectral Materials, where Jaye collaborated on microbial tests for functional coatings and drug delivery products. Jaye also has experience as a Postdoctoral Fellow at the University of Toronto, leading research on host-pathogen interactions and mentoring graduate students. Jaye earned a PhD in Microbiology from Zhejiang University in 2015.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.